CD33 and neoplasm: Tumor analysis of the microPET data using VOIs showed significant blocking of 89Zr-lintuzumab in the group pre-treated with naive lintuzumab (pre-blocked group), thus indicating specific targeting of CD33 on OCI-AML3 cells in vivo.